Clinical Trials - Physician

Clinical Trials - Physician

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
A Study Comparing Venetoclax + Fulvestrant vs Fulvestrant In Women with Estrogen Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Abemaciclib and CDK4/6 Inhibitor in Combination with Fulvestrant Compared to Chemotherapy in Women with Hormone Positive, HER2 negative Advanced Breast Cancer with Visceral Metastasis (I3Y-MC-JPCU)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of ASP1948, Targeting Immune Modulatory Receptor in Subjects with Advanced Solid Tumors (1948-CL-0101 I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor GIST (18016) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Brigatinib in Patients with ALK+ Advanced NonSmall Cell Lung Cancer who have Progressed on Alectinib or Ceritinib (18076)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Cabozantinib Compared with Placebo in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR targeted Therapy (XL184-311)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Copanlisib in Combination with Standard Immunochemotherapy vs Standard Immunochemotherapy in Relapsed Indolent NonHodgkins Lymphoma (CHRONOS-4) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Daratumumab/rHuPH20 Plus Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant MaintenanceTherapy in Patients with Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (S1803) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Dostarlimab vs Pembrolizumab in Combination with Chemotherapy with Extension to Dostarlimab in Combination with TIM-3 Inhibitor TSR-022 for Metastatic NonSmall Cell Lung Cancer with No Prior Treament for Metastatic Disease (18189) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of FT-2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation (FT-2012) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum Based Regimen or Anti-PD-1/PD-L-1 Based Immunotherapy (18283) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of IMO-2125 in Combination with Ipilimumab vs Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of INCMGA00012 in Patients with Squamous Carcinoma of the Anal Canal who have Progressed Following Platinum Based Chemotherapy (18134) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Ipilimumab, Cabozantinib and Nivolumab in Rare Genitourinary Tumors (A031702) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of MGCD516 in Patients with Advanced Solid Tumors (17038) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Neoadjuvant Chemotherapy Alone vs Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab+BMS986205 Followed by Post Surgery Therapy with Nivolumab or Nivolumab+BMS986205 in Pts with Muscle Invasive Bladder CA (18095) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of NKTR-262 in Combination with NKTR-214 and with NKTR-214 Plus Nivolumab In Patients with Locally Advanced or Metastatic Solid Tumors of Urothelial or Renal Origin (REVEAL)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Osimertinib in Advanced NonSmall Cell Lung Cancer Patients with Exon20 Mutations in EGFR (EA5162) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Pembrolizumab + Olaparib vs Abiraterone or Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (MK7339-010) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Pembrolizumab and Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary (GY016) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of REGN5678 with Cemiplimab in Patients with Metastatic Castration Resistant Prostate Cancer (R5678-ONC-1879) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Regorafenib and Anti-PD-1 in Patients with Microsatellite Stable Colorectal Cancer (19096) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Rigosertib vs Physician Choice of Treatment in Patients with Myelodysplastic Syndrome After Failure with Hypomethylating Agent (INSPIRE) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Ruxolitinib with Front Line Neoadjuvant and Post Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (GY007) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Sitravatinib in Combination with Nivolumab vs Docetaxel in Patients with Advanced Nonsquamous Nonsmall Cell Lung Cancer with Disease Progression on or after Platinum Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy(MRT516005) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members